THE WHAT? Hugel reported record first-half 2026 sales, operating profit and net income, driven by growing international demand for its botulinum toxin portfolio alongside continued expansion in dermal fillers, skinboosters and cosmetics.
THE DETAILS Hugel’s H1 consolidated sales increased 27.2% year-on-year to KRW254.5 billion, while operating profit rose 8.4% to KRW103.7 billion and net income climbed 23.5% to KRW85.3 billion. Q2 sales increased 25.1% to a record KRW137.9 billion, although operating profit slipped 1.1% year-on-year to KRW56 billion as Hugel invested in its US direct-sales operations and marketing. Botulinum toxin remained the main growth driver, with H1 sales rising 46.6% to KRW149.4 billion, while sales in the Americas more than doubled. The cosmetics and other businesses also grew 31.7% to KRW39 billion in H1, with Q2 sales increasing 32.8% to KRW19.8 billion.
THE WHY? Hugel’s performance demonstrates the increasing international reach of Korean medical aesthetics businesses, with the Americas emerging as an important growth engine. Growth in cosmetics alongside injectables also supports Hugel’s strategy of building a broader portfolio across the medical aesthetics and beauty markets.
Source: Hugel
